Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 539

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 539
---
 changes to perform the terms of this Section 5.19. 2.Section 8.10 is amended to include the following definitions of defined term: “ Beneficial Ownership Limitation ” shall mean 9.99% of the number of the Parent Common Stock outstanding immediately after giving effect to the issuance of the Merger Consideration. 3.Further, notwithstanding Section 7.1.1 of the Agreement, the Termination Date shall be extended from January 31, 2025, to April 30, 2025. 4.Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to such terms as set forth in the Agreement. 5.This Amendment shall be effective as of the day and year first written above. Except as amended hereby, and as so amended, the Agreement shall remain in full force and effect and shall be otherwise unaffected hereby, this Amendment does not constitute, directly or by implication, an amendment or waiver of any provision of the Agreement or any ancillary document, or any other right, remedy, power or privilege of any party, except as expressly set forth herein. 6.The Agreement, as amended by this Amendment, and the documents or instruments attached hereto or thereto or referenced herein or therein, constitutes the entire agreement between the Parties with respect to the subject matter of the Agreement, and supersedes all prior agreements and understandings, both oral and written, between the Parties with respect to its subject matter. 7.This Amendment may be executed in separate counterparts, each of such counterparts shall for all purposes be deemed to be an original and all such counterparts shall together constitute but one and the same instrument. [signature page follows] Annex A-64

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized signatories as of the date first indicated above.

| PARENT                 |     |                        |     |                         |
| NLS PHARMACEUTICS LTD. |     |                        |     |                         |
| By                     |     | /s/ Alexander C. Zwyer |     |                         |
|                        |     | Name:                  |     | Alexander C. Zwyer      |
|                        |     | Title:                 |     | Chief Executive Officer |
| By                     |     | /s/ Ronald Hafner      |     |                         |
|                        |     | Name:                  |     | Ronald Hafner           |
|                        |     | Title: